Hyundai Bioscience Co. Ltd (048410) - Total Liabilities
Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) has total liabilities worth ₩17.12 Billion KRW (≈ $11.60 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 048410 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Hyundai Bioscience Co. Ltd - Total Liabilities Trend (2002–2025)
This chart illustrates how Hyundai Bioscience Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Hyundai Bioscience Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
Hyundai Bioscience Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Hyundai Bioscience Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Smcp SAS
PA:SMCP
|
France | €978.00 Million |
|
Shanxi Antai Group Co Ltd
SHG:600408
|
China | CN¥2.94 Billion |
|
Beijing Kaiwen Education Technology Co Ltd
SHE:002659
|
China | CN¥763.04 Million |
|
Pubang Landscape Architecture Co Ltd
SHE:002663
|
China | CN¥2.11 Billion |
|
Nathans Famous Inc
NASDAQ:NATH
|
USA | $67.87 Million |
|
PT Temas Tbk
JK:TMAS
|
Indonesia | Rp2.14 Trillion |
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
USA | $20.27 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Hyundai Bioscience Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Hyundai Bioscience Co. Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hyundai Bioscience Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hyundai Bioscience Co. Ltd (2002–2025)
The table below shows the annual total liabilities of Hyundai Bioscience Co. Ltd from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩20.01 Billion ≈ $13.56 Million |
-29.20% |
| 2024-12-31 | ₩28.27 Billion ≈ $19.16 Million |
+275.85% |
| 2023-12-31 | ₩7.52 Billion ≈ $5.10 Million |
-17.28% |
| 2022-12-31 | ₩9.09 Billion ≈ $6.16 Million |
-52.04% |
| 2021-12-31 | ₩18.96 Billion ≈ $12.85 Million |
-53.86% |
| 2020-12-31 | ₩41.09 Billion ≈ $27.85 Million |
+152.92% |
| 2019-12-31 | ₩16.25 Billion ≈ $11.01 Million |
+20.13% |
| 2018-12-31 | ₩13.52 Billion ≈ $9.17 Million |
-27.32% |
| 2017-12-31 | ₩18.61 Billion ≈ $12.61 Million |
-47.09% |
| 2016-12-31 | ₩35.17 Billion ≈ $23.83 Million |
+86.97% |
| 2015-12-31 | ₩18.81 Billion ≈ $12.75 Million |
+82.23% |
| 2014-12-31 | ₩10.32 Billion ≈ $6.99 Million |
+14.19% |
| 2013-12-31 | ₩9.04 Billion ≈ $6.13 Million |
-31.33% |
| 2012-12-31 | ₩13.16 Billion ≈ $8.92 Million |
-19.23% |
| 2011-12-31 | ₩16.30 Billion ≈ $11.04 Million |
-0.42% |
| 2010-12-31 | ₩16.37 Billion ≈ $11.09 Million |
-25.22% |
| 2009-12-31 | ₩21.89 Billion ≈ $14.83 Million |
-41.11% |
| 2008-12-31 | ₩37.17 Billion ≈ $25.19 Million |
-17.26% |
| 2007-12-31 | ₩44.92 Billion ≈ $30.44 Million |
-69.25% |
| 2006-12-31 | ₩146.06 Billion ≈ $98.99 Million |
-23.73% |
| 2005-12-31 | ₩191.51 Billion ≈ $129.78 Million |
+16.88% |
| 2004-12-31 | ₩163.86 Billion ≈ $111.04 Million |
-5.94% |
| 2003-12-31 | ₩174.21 Billion ≈ $118.06 Million |
+27.61% |
| 2002-12-31 | ₩136.52 Billion ≈ $92.52 Million |
-- |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.